Schott and Credence MedSystems collaborate on injection safety

Published: 5-Oct-2020

The two companies will work together an offering for the delivery of injectable medications via prefilled syringes

Credence MedSystems and Schott have formed a collaboration for the application of Credence's Companion technology with Schott’s pre-fillable syriQ glass and Toppac polymer syringe systems.

Credence says its Companion Safety Syringe system provides usability and safety features to end-users while integrating with existing syringe barrels and primary packaging components. At the completion of the injection, there is a click signalling the dose has been delivered, and the needle automatically retracts into the syringe barrel to preventing reuse.

Bringing together the Companion technology and Schott's syringes, this partnership targets a pre-validated and pre-assembled portfolio of passive integrated needle systems with various available syringe sizes made of both glass and Cyclic Olefin Copolymer materials.

“Integrating our established Companion technology with a broad variety of existing syringe barrels from Schott is an important milestone in offering Innovation Without Change to the pharmaceutical industry,” said John Merhige, Credence’s Chief Commercial Officer. “This allows pharma the confidence to work with already validated systems but the freedom to choose the perfect fit from a wide portfolio.”

Fabian Stöcker, VP Global Strategy & Innovation at Schott Pharmaceutical Systems said: “Having over 20 years of experience in the field of syringes, we are happy that, with this partnership and product offering, we can even go a step further to create a new, synergistic and trusted offering for glass and polymer syringe systems that is responsive to the growing needs of the industry. To our knowledge, we will provide the first integrated needle safety system on the market with a polymer pre-fillable syringe by integrating the Credence Companion technology into our Schott Toppac syringes.”

The companies are currently in the process of defining implementation timelines and product offerings in advance of communication with their pharmaceutical customers.

You may also like